Announcements Trials
Browse Landscape

Phase

Phase 1 1

Status

Withdrawn 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Plasma cell 1Other hematologic neoplasm 1

Conditions

Breast Neoplasms 14Lymphoma 10Lymphoma, Large B-Cell, Diffuse 8Triple Negative Breast Neoplasms 6Lymphoma, Follicular 5Precursor T-Cell Lymphoblastic Leukemia-Lymphoma 3Lymphoma, Non-Hodgkin 3Lymphoma, Mantle-Cell 3Carcinoma, Hepatocellular 3Waldenstrom Macroglobulinemia 2Sarcoma 2Ovarian Neoplasms 2Lymphoma, Large-Cell, Anaplastic 2Lymphoma, Extranodal NK-T-Cell 2Immunoblastic Lymphadenopathy 2Enteropathy-Associated T-Cell Lymphoma 2Dendritic Cell Sarcoma, Interdigitating 2Burkitt Lymphoma 2Vomiting 1Urinary Bladder Neoplasms 1Urethral Neoplasms 1Ureteral Neoplasms 1Sezary Syndrome 1Rhabdomyosarcoma 1Recurrence 1Precursor Cell Lymphoblastic Leukemia-Lymphoma 1Precursor B-Cell Lymphoblastic Leukemia-Lymphoma 1Platinum-Refractory Fallopian Tube Carcinoma 1Pancreatic Neoplasms 1Neuroectodermal Tumors, Primitive, Peripheral 1

Interventions

liposomal doxorubicin 1dexamethasone acetate 1dexamethasone 21-phosphate 1daratumumab 1auricularum 1Lenalidomide 1Doxorubicin 1Dexamethasone 1Calcium Dobesilate 1Bortezomib 1Bendamustine Hydrochloride 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Withdrawn × Leukemia, Plasma Cell × Doxorubicin × Clear all
NCT03591744 2018-12-19

Daratumumab, Bortezomib, Dexamethasone, Pegylated Liposomal Doxorubicin Hydrochloride, and Lenalidomide in Treating Participants With Plasma Cell Leukemia

City of Hope Medical Center

Phase 1 Withdrawn
Other hematologic neoplasmPlasma cell

Leukemia, Plasma Cell

Data powered by HemOnc (CC BY 4.0) Colophon âš¡